With cash running low, Swedish cell therapy company looks to sell off platform
30 May 2023
Cell TherapyAcquisition
Small cell therapy company Idogen will have to liquidate the company if another solution isn’t found soon, like a reverse merger or the sale of its platform, as its cash dwindles.
On Tuesday, Sweden-listed Idogen (STO: $IDOGEN) said it had started conversations around a reverse merger – but there isn’t much time, as a proposal for liquidation will be discussed at its annual general meeting on June 8. Idogen added that unless its technology platform is sold and “yields the desired result,” shareholders can’t count on any financial gain in the case of liquidation.
Preview
Source: EndPoints
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.